0000000000331373

AUTHOR

Raul Urrutia

showing 3 related works from this author

Nupr1-Aurora Kinase A Pathway Provides Protection against Metabolic Stress-Mediated Autophagic-Associated Cell Death

2012

Abstract Purpose: The limited supply of oxygen and nutrients is thought to result in rigorous selection of cells that will eventually form the tumor. Experimental Design: Nupr1 expression pattern was analyzed in human tissue microarray (TMA) and correlated with survival time of the patient. Microarray analysis was conducted on MiaPaCa2 cells subjected to metabolic stress in Nupr1-silenced conditions. DNA repair and cell cycle–associated gene expression was confirmed by real-time quantitative PCR (qRT-PCR). Nupr1 and AURKA protective role were analyzed using RNA interference (RNAi) silencing or overexpression. DNA damage and autophagy were analyzed by Western blot analysis and immunofluoresc…

Cancer ResearchProgrammed cell deathCell SurvivalDNA damageDNA repairAdenocarcinomaProtein Serine-Threonine KinasesBiologyAurora KinasesStress PhysiologicalCell Line TumorAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansGene silencingAurora Kinase ARegulation of gene expressionGene knockdownMicroarray analysis techniquesAURKA GeneMolecular biologyCell HypoxiaNeoplasm ProteinsCell biologyGene Expression Regulation NeoplasticGlucoseOncologyRNA InterferenceCarcinoma Pancreatic DuctalClinical Cancer Research
researchProduct

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.

2013

The incidence of pancreatic adenocarcinoma is increasing with more than 43,000 predicted new cases in the US and 65,000 in Europe this year. Pancreatic cancer patients have a short life expectancy with less than 3–4% 5-y survival, which results in an equivalent incidence and mortality rate. One of the major challenges in pancreatic cancer is the identification of pharmacological approaches that overcome the resistance of this cancer to therapy. Intensive research in the past decades has led to the classification of pancreatic cancers and the identification of the driver key genetic events. Despite the advances in understanding the molecular mechanisms responsible for pancreatic cancer patho…

Oncologymedicine.medical_specialtyCell SurvivalDrug resistanceDiseaseBiologyProtein Serine-Threonine KinasesModels BiologicalAurora KinasesStress PhysiologicalPancreatic cancerInternal medicineCarcinomamedicineAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansMolecular BiologyCell DeathMechanism (biology)Mortality rateCancerCell Biologymedicine.diseaseAutophagic PunctumNeoplasm ProteinsEndocrinologyDrug Resistance NeoplasmAdenocarcinomaCarcinoma Pancreatic DuctalAutophagy
researchProduct

Assessing Human Genetic Variations in Glucose Transporter SLC2A10 and Their Role in Altering Structural and Functional Properties

2018

Purpose: Demand is increasing for clinical genomic sequencing to provide diagnoses for patients presenting phenotypes indicative of genetic diseases, but for whom routine genetic testing failed to yield a diagnosis. DNA-based testing using high-throughput technologies often identifies variants with insufficient evidence to determine whether they are disease-causal or benign, leading to categorization as variants of uncertain significance (VUS). Methods: We used molecular modeling and simulation to generate specific hypotheses for the molecular effects of variants in the human glucose transporter, GLUT10 (SLC2A10). Similar to many disease-relevant membrane proteins, no experimentally derived…

0301 basic medicineMolecular modellcsh:QH426-470Computational biologyBiology03 medical and health scienceschemistry.chemical_compoundGenetic variationmedicinegeneticsnatural variationGenetics (clinical)Genetic testingOriginal Researchmedicine.diagnostic_testmolecular modelingvariant of uncertain significanceGlucose transporterPrecision medicinePhenotypelcsh:Genetics030104 developmental biologychemistryMembrane proteinATSMolecular MedicineDNAFrontiers in Genetics
researchProduct